Angiotensin-Converting Enzyme 2 (Ace2) Receptor and Sars-Cov-2: Potential Therapeutic Targeting Publisher Pubmed



Sharifkashani S^{1, 2} ; Bafrani MA^{1, 3} ; Khaboushan AS^{1, 2} ; Pirzadeh M^{1, 4} ; Kheirandish A^{1, 5} ; Yavarpourbali H^{1, 4} ; Hessami A^{1, 6} ; Saghazadeh A^{1, 7} ; Rezaei N^{7, 8, 9}
Source: European Journal of Pharmacology Published:2020

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus that uses the human angiotensin-converting enzyme 2 (ACE2) receptor as a point of entry. The present review discusses the origin and structure of the virus and its mechanism of cell entry followed by the therapeutic potentials of strategies directed towards SARS-CoV2-ACE2 binding, the renin-angiotensin system, and the kinin-kallikrein system. SARS-CoV2-ACE2 binding-directed approaches mainly consist of targeting receptor binding domain, ACE2 blockers, soluble ACE2, and host protease inhibitors. In conclusion, blocking or manipulating the SARS-CoV2-ACE2 binding interface perhaps offers the best tactic against the virus that should be treated as a fundamental subject of future research. © 2020 Elsevier B.V.